Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy

Author： Wonnacott K.   Lavoie D.   Fiorentino R.   McIntyre M.   Huang Y.   Hirschfeld S.  

Publisher： Ashgate Publishing Ltd

ISSN： 1465-3249

Source： Cytotherapy, Vol.10, Iss.3, 2008-03, pp. : 312-316

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adoptive immunotherapy — the Food and Drug Administration and you: a regulatory framework for manipulated cellular products

By Keane-Moore M  

Cytotherapy, Vol. 4, Iss. 5, 2002-09 ,pp. : 451-453

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Adoptive immunotherapy, the Food and Drug Administration and you: a regulatory approach to donor lymphocytes

By Lazarus E  

Cytotherapy, Vol. 4, Iss. 5, 2002-09 ,pp. : 449-449

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Standardization of cell analysis methods in clinical cellular therapy programs: a challenge for ISCT

By Gratama Jw   Kvalheim G   Orfao A  

Cytotherapy, Vol. 8, Iss. 6, 2006-12 ,pp. : 528-529

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Current translational and clinical practices in hematopoietic cell and gene therapy

By Digiusto David L.   Kiem Hans-Peter  

Cytotherapy, Vol. 14, Iss. 7, 2012-08 ,pp. : 775-790

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma1

By Cooper Ljn   Ausubel L   Gutierrez M   Stephan S   Shakeley R   Olivares S   Serrano Lm   Burton L   Jensen McV   Forman Sj   Digiusto Dl  

Cytotherapy, Vol. 8, Iss. 2, 2006-05 ,pp. : 105-117

Ashgate Publishing Ltd

Access to resources Recommend Favorite